Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events

被引:105
作者
Mora, Samia
Rifai, Nader
Buring, Julie E.
Ridker, Paul M.
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Donald W Reynolds Ctr Cardiovasc Res, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Lequcq Ctr Mol & Genet Epidemiol, Boston, MA 02215 USA
[4] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA
[5] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02215 USA
[6] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[7] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA
关键词
acute-phase proteins; C-reactive protein; fibrinogen; inflammation; women;
D O I
10.1161/CIRCULATIONAHA.106.634089
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background - Current guidelines suggest measuring high-sensitivity C-reactive protein (hs-CRP) as an aid to coronary risk assessment in adults without cardiovascular disease (CVD). Whether other inflammatory biomarkers, such as fibrinogen, add further prognostic information is uncertain. Methods and Results - In a prospective study of 27 742 initially healthy middle-aged women, the associations of baseline immunoassay fibrinogen and hs-CRP measurements with incident CVD were examined over a 10-year follow-up period. Compared with women in the bottom biomarker quintile, age-adjusted hazard ratios (95% confidence intervals [CIs]) for incident CVD for quintiles 2 to 5 of fibrinogen were 1.10 (0.86 to 1.41), 1.30 (1.03 to 1.65), 1.46 (1.16 to 1.85), and 2.43 (1.95 to 3.02); for hs-CRP they were 1.48 (1.06 to 2.05), 1.70 (1.24 to 2.33), 2.20 (1.63 to 2.96), and 3.24 (2.43 to 4.31). After further adjustment for established risk factors, both biomarkers remained associated (P for trend <= 0.001) with incident CVD (hazard ratio, 1.35; 95% CI, 1.07 to 1.71 for top fibrinogen quintile; and hazard ratio, 1.68; 95% CI, 1.22 to 2.29 for top hs-CRP quintile compared with the bottom quintiles). Further adjustment for the other biomarker resulted in hazard ratios of 1.23 and 1.56 (P for trend = 0.02 and 0.002), respectively. Although fibrinogen correlated positively with hs-CRP (rs = 0.41, P < 0.001), the highest CVD risk was associated with elevated levels of both fibrinogen and hs-CRP: age-adjusted hazard ratio of 3.45 (95% CI, 2.60 to 4.57) for women with fibrinogen > 393 mg/dL and hs-CRP > 3 mg/L compared with < 329 mg/dL and < 1 mg/L, respectively. Conclusions - In this cohort of initially healthy women, baseline levels of fibrinogen measured with a high-quality immunoassay provided additive value to hs-CRP and traditional risk factors in predicting incident CVD.
引用
收藏
页码:381 / 387
页数:7
相关论文
共 36 条
[1]
Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic [J].
Acevedo, M ;
Pearce, GL ;
Kottke-Marchant, K ;
Sprecher, DL .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (06) :1042-1045
[2]
Low-dose aspirin in the primary prevention of cancer the women's health study: A randomized controlled trial [J].
Cook, NR ;
Lee, IM ;
Gaziano, JM ;
Gordon, D ;
Ridker, PM ;
Manson, JE ;
Hennekens, CH ;
Buring, JE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (01) :47-55
[3]
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality - An individual participant meta-analysis [J].
Danesh, J ;
Lewington, S ;
Thompson, SG ;
Lowe, GDO ;
Collins, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14) :1799-1809
[4]
Despres J P, 1998, Obes Res, V6 Suppl 1, p8S
[5]
EASTHAM RD, 1963, LANCET, V2, P1196
[6]
Folsom A R, 1992, Ann Epidemiol, V2, P481
[7]
Prospective study of hemostatic factors and incidence of coronary heart disease - The Atherosclerosis Risk in Communities (ARIC) Study [J].
Folsom, AR ;
Wu, KK ;
Rosamond, WD ;
Sharrett, AR ;
Chambless, LE .
CIRCULATION, 1997, 96 (04) :1102-1108
[8]
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease - Application to Clinical and Public Health Practice - Report from the population science discussion group [J].
Fortmann, SP ;
Ford, E ;
Criqui, MH ;
Folsom, AR ;
Harris, TB ;
Hong, YL ;
Pearson, TA ;
Siscovick, D ;
Vinicor, F ;
Wilson, PF .
CIRCULATION, 2004, 110 (25) :E554-E559
[9]
Obesity, metabolic syndrome, and coronary atherosclerosis [J].
Grundy, SM .
CIRCULATION, 2002, 105 (23) :2696-2698
[10]
Emerging risk factors for atherosclerotic vascular disease - A critical review of the evidence [J].
Hackam, DG ;
Anand, SS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07) :932-940